P.043 Plasmapheresis for treatment of light chain amyloidosis related myopathy

Background: Light chain (AL) amyloidosis is a plasma cell disorder characterized by abnormal fibrillary light deposition causing cardiac, renal, hepatic, gastrointestinal and peripheral nervous system dysfunction. Muscle disease occurs in 1.5% of individuals progressive proximal weakness thus far considered untreatable. Methods: We reviewed two cases AL associated myopathy at our institution who had robust response to plasmapheresis. Both were stringent clinical following CyBorME therapy during peak severity their myopathy. Results: In case 1, 70-year-old male with recently diagnosed kappa multiple myeloma cardiac/renal developed severe subacute preventing ambulation. CK was normal electromyography consistent irritable Deltoid biopsy showed perimysial endomysial amyloidosis. A trial plasmapheresis tapering schedule resulted recovery strength. 2, 67-year-old female on fat pad aspirate requiring prolonged hospital admission. demonstrated non-irritable Bicep perivascular Conclusions: Plasmapheresis novel potentially effective treatment for patients